Groove Health, Inc.

Groove Health, Inc. is a healthcare technology company focused on enhancing medication management through its AI-driven platform, facilitating better patient outcomes and streamlined communication between healthcare providers and patients. Founded in 2016 and headquartered in Chicago, US, Groove Health, Inc. offers innovative solutions for medication management.

The company previously raised USD 1. 6 mn in Seed funding on August 8, 2017, engaging in a single transaction. The company is led by CEO Andrew Hourani, who has experience in the healthcare sector. Groove Health, Inc.

specializes in medication management through its core offering, the Intelligent Medication Cloud, an AI-powered platform designed to enhance medication adherence and optimize care delivery. The platform connects patients, care teams, and healthcare enterprises, providing features such as personalized medication reminders, documentation tools, and analytical insights. The primary end-users include healthcare providers, patients, health systems, and pharmaceutical companies, all benefiting from improved medication adherence and reduced adverse drug events (ADEs). Groove Health, Inc.

's revenue model is based on subscription services, allowing healthcare providers and organizations access to the Intelligent Medication Cloud and its suite of tools. Organizations typically partner with Groove Health to integrate the platform into their existing systems, which facilitates a streamlined workflow for medication management. Subscription fees vary depending on the size of the organization and specific features utilized, allowing for scalable solutions tailored to different client needs. The company plans to utilize its recent Seed funding of USD 1.

6 mn to develop upcoming products aimed at enhancing user experience and optimizing medication management. Additionally, Groove Health, Inc. is looking to expand into new markets, specifically targeting international regions that demonstrate a need for improved medication adherence solutions by the end of 2023. This strategic approach reflects the company's commitment to addressing the complexities of medication management both in the US and abroad.